Clinical Trial

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Study acronym: WU-KONG20
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-04.
Trial Details
NCT Number NCT06864624
Lead Sponsor Tang-Du Hospital
Collaborators: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Conditions NSCLC
Enrollment 27 participants
Start Date 2025-02-18
Primary Completion 2026-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-25